SCHEMBL6323504

SCHEMBL6323504

NCC(O)c1cc(Cl)c(N)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 5/20 0.56
LMNA P02545 3/20 0.56
ADRB2 P07550 3/20 0.56
ADRA1A P35348 2/20 0.56
TSHR P16473 2/20 0.56
HTR1A P08908 1/20 0.56
SLC6A2 P23975 1/20 0.56
SLC6A4 P31645 1/20 0.56
OPRK1 P41145 1/20 0.56
SLC6A3 Q01959 1/20 0.56
CYP3A4 P08684 3/20 0.54
KDM4E B2RXH2 3/20 0.54
TAAR1 Q96RJ0 3/20 0.44
APEX1 P27695 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
RECQL P46063 2/20 0.44
BLM P54132 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3983553 1.00 ADRB1 (0.56) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL7147396 0.87 ADRB1 (0.45) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL7150188 0.84 HPGD (0.45) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL6476992 0.82 ADRB2 (0.55) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL10493809 0.82 ADRB1 (0.42) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL8789051 0.81 ADRB1 (0.54) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL7151236 0.81 LMNA (0.42) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL8789044 0.81 ADRB1 (0.54) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL8402182 0.77 BLM (0.47) ADRB1LMNAADRB2ADRA1ATSHR
SCHEMBL7151603 0.77 BLM (0.47) ADRB1LMNAADRB2ADRA1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113960305-B Immunomagnetic bead for clenbuterol Luo Fuji purification and preparation method and application thereof 北京勤邦科技股份有限公司 2023-10-17 CN claimed
CN-113960305-A Immunomagnetic bead for clenbuterol enrichment and purification and preparation method and application thereof 北京勤邦生物技术有限公司 2022-01-21 CN claimed
CN-113960305-B Immunomagnetic bead for clenbuterol Luo Fuji purification and preparation method and application thereof 北京勤邦科技股份有限公司 2023-10-17 CN disclosed
CN-113960305-A Immunomagnetic bead for clenbuterol enrichment and purification and preparation method and application thereof 北京勤邦生物技术有限公司 2022-01-21 CN disclosed
US-6933296-B2 Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors ALTANA PHARMA B.V. (NL) 2005-08-23 US disclosed
US-20050070515-A1 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-03-31 US disclosed
EP-0998484-B1 METHOD OF IDENTIFYING COMPOUNDS HAVING REDUCED SYSTEMIC EFFECTS GLAXO GROUP LTD (GB) 2004-03-03 EP disclosed
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ALTANA PHARMA B.V. (NL) 2003-10-16 US disclosed
EP-1296956-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA Pharma AG (DE) 2003-04-02 EP disclosed
US-20020019378-A1 COMPOUNDS GLAXO WELLCOME INC. 2002-02-14 US disclosed
WO-2001094319-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA PHARMA AG (DE) 2001-12-13 WO disclosed
US-4921867-A Pyridine compounds useful for therapy or prophylaxis of a disease associated with airway obstruction GLAXO GROUP LIMITED (GB) 1990-05-01 US disclosed
EP-0322164-A2 Ethanolamine derivatives GLAXO GROUP LIMITED (GB) 1989-06-28 EP disclosed
EP-0303464-A2 Chloroaniline derivatives GLAXO GROUP LIMITED (GB) 1989-02-15 EP disclosed
EP-0303466-A2 Ethanolamine derivatives GLAXO GROUP LIMITED (GB) 1989-02-15 EP disclosed
EP-0286242-A2 Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 1988-10-12 EP disclosed
EP-0278728-A2 1-(4-Amino-3,5-dichlorophenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease GLAXO GROUP LIMITED (GB) 1988-08-17 EP disclosed
EP-0236624-A2 Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-09-16 EP disclosed
EP-0181709-A1 Dichloroaniline Derivatives GLAXO GROUP LIMITED (GB) 1986-05-21 EP disclosed
EP-0030030-A1 Derivatives of 2-aminoethanol, processes for their preparation, pharmaceutical compositions containing such compounds and the use the latter CIBA-GEIGY AG (CH) 1981-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019378-A1 COMPOUNDS ATP6V1E1, PSME1, ATP6V1H ADRB1 4093/4885LMNA 3880/4885ADRB2 3885/4885
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ADRB1, ADRB2, ADRA1D ADRB1 1/4885LMNA 3762/4885ADRB2 2/4885
US-20050070515-A1 Compounds LCT, LPO, LIPE ADRB1 4039/4885LMNA 3427/4885ADRB2 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.